pipecolic acids

Summary

Top Publications

  1. ncbi A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease
    Patrick T Murray
    Nephrology Section, University of Chicago, Chicago, Illinois 60657, USA
    Kidney Int 66:2446-53. 2004
  2. ncbi Heparin-induced thrombocytopenia: diagnosis and management
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Circulation 110:e454-8. 2004
  3. ncbi Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients
    John R Bartholomew
    The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Drugs Aging 24:489-99. 2007
  4. ncbi Excessive argatroban anticoagulation for heparin-induced thrombocytopenia
    Marc G Reichert
    Department of Pharmacy, Wake Forest University Baptist Medical Center, Winston Salem, NC 27157 1163, USA
    Ann Pharmacother 37:652-4. 2003
  5. ncbi Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
    B E Lewis
    Loyola University Medical Center, Maywood, Illinois, USA
    Circulation 103:1838-43. 2001
  6. ncbi Argatroban anticoagulation in patients with heparin-induced thrombocytopenia
    Bruce E Lewis
    Department of Cardiology, Loyola University Medical Center, Maywood, Ill, USA
    Arch Intern Med 163:1849-56. 2003
  7. ncbi Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction
    David R Williamson
    Department of Pharmacy Services, Hopital du Sacre Coeur de Montreal, Montreal, Quebec, Canada
    Pharmacotherapy 24:409-14. 2004
  8. ncbi Effect of renal function on the pharmacodynamics of argatroban
    Paul A Arpino
    Department of Pharmacy, Massachusetts General Hospital, Boston, MA 02114, USA
    Ann Pharmacother 38:25-9. 2004
  9. ncbi Heparin-induced thrombocytopenia in intensive care patients
    Kathleen Selleng
    Department of Immunology and Transfusion Medicine, Ernst Moritz Arndt Universitat, Greifswald, Germany
    Crit Care Med 35:1165-76. 2007
  10. ncbi Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy
    Bharathi V Reddy
    Section of Nephrology, University of Chicago, IL 60637, USA
    Ann Pharmacother 39:1601-5. 2005

Detail Information

Publications194 found, 100 shown here

  1. ncbi A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease
    Patrick T Murray
    Nephrology Section, University of Chicago, Chicago, Illinois 60657, USA
    Kidney Int 66:2446-53. 2004
    ..We prospectively evaluated 3 treatment regimens of argatroban, a direct thrombin inhibitor, for providing adequate, safe anticoagulation in patients with end-stage renal disease (ESRD) during hemodialysis...
  2. ncbi Heparin-induced thrombocytopenia: diagnosis and management
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Circulation 110:e454-8. 2004
  3. ncbi Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients
    John R Bartholomew
    The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Drugs Aging 24:489-99. 2007
    ..Argatroban, a direct thrombin inhibitor that has reduced clearance in elderly versus younger volunteers, is used for thromboprophylaxis or treatment in heparin-induced thrombocytopenia (HIT)...
  4. ncbi Excessive argatroban anticoagulation for heparin-induced thrombocytopenia
    Marc G Reichert
    Department of Pharmacy, Wake Forest University Baptist Medical Center, Winston Salem, NC 27157 1163, USA
    Ann Pharmacother 37:652-4. 2003
    ..To report 4 patients who became excessively anticoagulated with the recommended or lower starting doses of argatroban during treatment for heparin-induced thrombocytopenia type II (HIT-II) in a cardiothoracic intensive care unit...
  5. ncbi Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
    B E Lewis
    Loyola University Medical Center, Maywood, Illinois, USA
    Circulation 103:1838-43. 2001
    ..We report a prospective, historical- controlled study evaluating the efficacy and safety of argatroban, a direct thrombin inhibitor, as anticoagulant therapy in patients with HIT or HIT with thrombosis syndrome (HITTS)...
  6. ncbi Argatroban anticoagulation in patients with heparin-induced thrombocytopenia
    Bruce E Lewis
    Department of Cardiology, Loyola University Medical Center, Maywood, Ill, USA
    Arch Intern Med 163:1849-56. 2003
    ..We describe our experience with argatroban, a direct thrombin inhibitor, in patients with HIT or HIT with thrombosis (HITTS)...
  7. ncbi Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction
    David R Williamson
    Department of Pharmacy Services, Hopital du Sacre Coeur de Montreal, Montreal, Quebec, Canada
    Pharmacotherapy 24:409-14. 2004
    ..To demonstrate dosing adjustment difficulties of argatroban encountered in critically ill patients with acute liver dysfunction who are receiving continuous renal replacement therapy...
  8. ncbi Effect of renal function on the pharmacodynamics of argatroban
    Paul A Arpino
    Department of Pharmacy, Massachusetts General Hospital, Boston, MA 02114, USA
    Ann Pharmacother 38:25-9. 2004
    ..Argatroban is a direct thrombin inhibitor used to treat heparin-induced thrombocytopenia (HIT). Argatroban is primarily cleared by hepatic mechanisms, with only small amounts of unchanged drug cleared by the kidneys...
  9. ncbi Heparin-induced thrombocytopenia in intensive care patients
    Kathleen Selleng
    Department of Immunology and Transfusion Medicine, Ernst Moritz Arndt Universitat, Greifswald, Germany
    Crit Care Med 35:1165-76. 2007
    ....
  10. ncbi Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy
    Bharathi V Reddy
    Section of Nephrology, University of Chicago, IL 60637, USA
    Ann Pharmacother 39:1601-5. 2005
    ..5-3.0 times baseline. However, few argatroban-treated patients with HIT and renal failure requiring renal replacement therapy (RRT) have been described...
  11. ncbi Argatroban anticoagulation in critically ill patients
    Martin Beiderlinden
    Klinik fur Anasthesiologie, Universitätsklinikum der Heinrich Heine Universität, Dusseldorf, Germany
    Ann Pharmacother 41:749-54. 2007
    ..Despite long-term use of argatroban in clinical practice, no dosing recommendations exist for critically ill patients with multiple organ dysfunction (MODS) and suspected or proven heparin-induced thrombocytopenia (HIT)...
  12. ncbi Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia
    Louis M Guzzi
    Florida Hospital, Orlando, FL, USA
    J Thromb Thrombolysis 22:169-76. 2006
    ..We retrospectively evaluated the effect of renal function on argatroban therapy in HIT patients with normal hepatic function, with the goal of refining dosing guidance, if needed...
  13. ncbi Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery
    Andreas Koster
    Department of Anesthesia, Deutsches Herzzentrum Berlin, Germany
    J Thorac Cardiovasc Surg 133:1376-7. 2007
  14. ncbi Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia
    Susan I O'Shea
    Divisions of Hematology and Nephrology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Semin Dial 16:61-7. 2003
    ..In this report the currently available alternatives to heparin for dialysis, including dosing and monitoring recommendations, are reviewed...
  15. ncbi Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients
    Anthony Gray
    Department of Pulmonary Medicine, Lahey Clinic, Burlington, Massachusetts 01805, USA
    Clin Appl Thromb Hemost 13:353-61. 2007
    ..Patients with more severe thrombocytopenia or HIT-related thrombosis on HIT diagnosis have a poorer prognosis, emphasizing the importance of prompt recognition/ treatment of HIT in acutely ill patients...
  16. ncbi Decreased argatroban clearance unaffected by hemodialysis in anasarca
    Simon de Denus
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA
    Ann Pharmacother 37:1237-40. 2003
    ..To report the case of a patient with acute renal failure and anasarca undergoing hemodialysis who demonstrated a prolonged effect of argatroban despite having no hepatic dysfunction...
  17. ncbi Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia
    Lawrence Rice
    The Methodist Hospital, Weill Cornell Medical College, Houston, Texas, USA
    J Clin Pharmacol 47:1028-34. 2007
  18. ncbi Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital
    Sandeep Kodityal
    Baylor College of Medicine, Houston, TX, USA
    J Intensive Care Med 21:86-92. 2006
    ..In contemporary "real world" use, argatroban provides safe and effective anticoagulation, strengthening the mandate to initiate alternative anticoagulation whenever heparin-induced thrombocytopenia appears likely...
  19. ncbi A comparison of lepirudin and argatroban outcomes
    Maureen A Smythe
    William Beaumont Hospital, Royal Oak, Michigan Wayne State University, Detroit, Michigan 48073, USA
    Clin Appl Thromb Hemost 11:371-4. 2005
    ..5% of lepirudin patients (p = .61). Major bleeding occurred in 10.3% and 11.5% of argatroban and lepirudin patients, respectively (p = 1.0). Argatroban and lepirudin demonstrated comparable safety and efficacy outcomes...
  20. ncbi Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial
    Andreas Koster
    Department of Anesthesia, Deutsches Herzzentrum Berlin, Berlin, Germany
    J Thorac Cardiovasc Surg 132:699-700. 2006
  21. ncbi Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia
    Tyree H Kiser
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Pharmacotherapy 25:1736-45. 2005
    ....
  22. ncbi Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction
    Robert L Levine
    University of Texas School of Medicine at Houston, 6431 Fannin, MSB 7 142, Houston, TX 77030, USA
    Chest 129:1167-75. 2006
    ..We evaluated the dosing requirements in argatroban-treated patients with heparin-induced thrombocytopenia (HIT) and hepatic dysfunction, and compared efficacy and safety outcomes with historical control patients...
  23. ncbi Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia
    Ignatius Y Tang
    Section of Nephrology, Department of Medicine, University of Chicago Hospitals, Chicago, IL 60637 1470, USA
    Ann Pharmacother 39:231-6. 2005
    ..Argatroban, a direct thrombin inhibitor, is an effective anticoagulant for patients who have heparin-induced thrombocytopenia (HIT). Anticoagulation is usually required for renal replacement therapy (RRT)...
  24. ncbi Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
    Bruce E Lewis
    Loyola University Medical Center, Maywood, Illinois, USA
    Catheter Cardiovasc Interv 57:177-84. 2002
    ..Overall, outcomes were comparable with those historically reported for heparin. Argatroban therefore is a reasonable anticoagulant option in this setting, where current options are limited...
  25. ncbi Argatroban for anticoagulation in continuous renal replacement therapy
    Andreas Link
    Klinik fur Innere Medizin III, Universitätsklinikum des Saarlandes D 66421Homburg Saar, Germany
    Crit Care Med 37:105-10. 2009
    ..The investigation focused on predictors for the maintenance doses of argatroban with efficacy and safety of argatroban being secondary outcomes...
  26. ncbi Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban
    Job Harenberg
    IV Department of Medicine, University Hospital Mannheim, Ruprecht Karls University Heidelberg, Theodor Kutzer Ufer 1 3, D 68167 Mannheim, Germany
    J Thromb Thrombolysis 19:65-9. 2005
    ....
  27. ncbi Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia
    Cathyyen H Dang
    Department of Pharmacy and Clinical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Pharmacotherapy 26:461-8. 2006
    ..To evaluate the efficacy, safety, and associated costs of anticoagulation with argatroban, bivalirudin, and lepirudin for managing patients with heparin-induced thrombocytopenia (HIT) or presumed HIT...
  28. ncbi Thrombin-directed inhibitors: pharmacology and clinical use
    C Michael White
    University of Connecticut, Hartford Hospital, Hartford, Conn 06102 5037, USA
    Am Heart J 149:S54-60. 2005
  29. ncbi Treatment of heparin-induced thrombocytopenia: a critical review
    Jack Hirsh
    Henderson Research Centre, Henderson Hospital, and the Department of Medicine, McMaster University, Hamilton, Ontario
    Arch Intern Med 164:361-9. 2004
    ....
  30. ncbi Heparin-induced thrombocytopenia: treatment options and special considerations
    William E Dager
    Department of Pharmaceutical Services, University of California Davis Medical Center, California 95817 2201, USA
    Pharmacotherapy 27:564-87. 2007
    ..Clinicians must become familiar with the available information on this serious adverse effect and its treatment so that optimum patient management strategies may be formulated...
  31. ncbi Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery
    Glenn S Murphy
    Department of Anesthesiology, Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, IL 60201, USA
    J Cardiothorac Vasc Anesth 21:113-26. 2007
  32. ncbi Heparin-induced thrombocytopenia and cardiovascular patients: recognition and treatment
    Kathy M Baker
    Virginia Commonwealth University, Richmond, VA 23298, USA
    Prog Cardiovasc Nurs 21:47-50. 2006
  33. ncbi The paradox of heparin-induced thrombocytopenia: the initial management
    Lisa M Taylor
    University of Kentucky Chandler Medical Center, Lexington, KY, USA
    Orthopedics 28:559-62. 2005
    ..The potential risk for heparin-induced thrombocytopenia should be suspected in postoperative patients who develop thrombocytopenia in the presence of heparin and low-molecular weight heparin agents...
  34. ncbi Heparin and other rapidly acting anticoagulants
    Thomas M Hyers
    Department of Internal Medicine, St Louis University School of Medicine, St Louis, MO, USA
    Semin Vasc Surg 18:130-3. 2005
    ..Ximelagatran (Exanta; AstraZeneca, Wilmington, DE) is an oral direct thrombin inhibitor under development for both acute and chronic anticoagulation...
  35. ncbi Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro
    Vance G Nielsen
    Department of Anesthesiology, The University of Alabama at Birmingham, Birmingham, Alabama 35249 6810, USA
    J Heart Lung Transplant 25:653-63. 2006
    ..An in vitro thrombelastographic assessment of the effects of DTIs on clot kinetics was consequently performed to determine potential causes for this complication...
  36. ncbi Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation
    Guy Young
    Department of Hematology, Children s Hospital of Orange County, Orange, California 92868, USA
    Blood Coagul Fibrinolysis 18:97-103. 2007
    ..The reduced bleeding reported with DTIs versus heparin may relate to the fact that clots form with normal rigidity and elasticity...
  37. ncbi Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia
    Jason T Call
    Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    Semin Thromb Hemost 30:297-304. 2004
    ....
  38. ncbi Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 149:S43-53. 2005
  39. ncbi Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management
    Lena M Napolitano
    Acute Care Surgery, Trauma, Burn, Critical Care, Emergency Surgery, Department of Surgery, University of Michigan Health System, Ann Arbor, MI, USA
    Crit Care Med 34:2898-911. 2006
    ..Although sepsis and hemodilution are more common etiologies of thrombocytopenia in critical illness, heparin-induced thrombocytopenia (HIT) is one potential etiology that warrants consideration...
  40. ncbi Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines
    Ahmet Tayfun Gurbuz
    Department of Cardio Thoracic Surgery, Tucson Medical Center, Tucson, AZ 85718, USA
    Eur J Cardiothorac Surg 27:138-49. 2005
    ..A high index of suspicion is required for timely diagnosis and treatment. Treatment is complex and outcome maybe less then satisfactory...
  41. ncbi Alternatives to heparin infusion
    Howard C Cook
    Department of Pharmacy Services, St Luke s Hospital, Bethlehem, Pennsylvania 18015, USA
    J Infus Nurs 27:413-24. 2004
    ..Current alternatives to heparin are reviewed...
  42. ncbi Heparin-induced thrombocytopenia and cardiovascular diseases
    Pranab Das
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0200, USA
    Am Heart J 152:19-26. 2006
  43. ncbi An anesthesia provider's perspective of heparin-induced thrombocytopenia
    Daniel Nay Woodyard
    United Anesthesia, Inc, Parkersburg, WVa, USA
    AANA J 73:115-9. 2005
    ..Clinical criteria and advanced serological testing are available for the definitive diagnosis of HIT. Clinical suspicion of HIT remains key to early cessation of heparin (all routes) and initiation of alternative treatments...
  44. ncbi Heparin-induced thrombocytopenia: advances in diagnosis and treatment
    Maureen F Cooney
    Westchester Medical Center in Valhalla, NY 10595, USA
    Crit Care Nurse 26:30-6; quiz 37. 2006
  45. ncbi Heparin-induced thrombocytopenia: principles for early recognition and management
    John R Bartholomew
    Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cleve Clin J Med 72:S31-6. 2005
    ..Once HIT is clinically suspected, heparin should be stopped immediately and direct thrombin inhibitor therapy started; waiting for laboratory confirmation may be catastrophic...
  46. ncbi Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients
    Lynn K Boshkov
    Department of Pathology and Medicine, Doernbecher Children s Hospital, Oregon Health and Science University, Portland, Oregon 97231, USA
    Ann Thorac Surg 81:S2355-9. 2006
    ....
  47. ncbi Heparin-induced thrombocytopenia without thrombosis: an evidence-based review of current literature
    Enda D O'Connor
    Toowoomba Health Service District, Toowoomba, QLD, Australia
    Crit Care Resusc 8:345-52. 2006
    ..answer the following questions: in a patient with isolated HIT, should alternative anticoagulation be commenced, what alternative agent should be used, what is the recommended duration of anticoagulation, and when should warfarin be used?..
  48. ncbi [Two surgical case reports showing atypical heparin-induced thrombocytopenia]
    C Hohnke
    Abteilung für Plastische und Wiederherstellungschirurgie, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munchen
    Chirurg 78:138, 140-1. 2007
    ..Due to frequent misinterpretations of heparin-induced unspecific skin reactions, especially in the absence of thrombocytopenia, we present two case reports which should increase the awareness of HIT's various clinical pictures...
  49. ncbi Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, New York 10022, USA
    Semin Thromb Hemost 30:305-14. 2004
    ..Optimal dosing regimens for argatroban, lepirudin, and bivalirudin should be further established in PCI patients...
  50. ncbi Argatroban, a new treatment option for heparin-induced thrombocytopenia
    Kevin W Cleveland
    Idaho Drug Information Service, Idaho State University College of Pharmacy, Pocatello, Idaho, USA
    Crit Care Nurse 23:61-6. 2003
  51. ncbi Argatroban as a primary or secondary postoperative anticoagulant in patients implanted with ventricular assist devices
    Louis E Samuels
    Department of Cardiothoracic Surgery, Lankenau Hospital, Wynnewood, Pennsylvania 19096, USA
    Ann Thorac Surg 85:1651-5. 2008
    ..We describe our experience with argatroban as a primary or secondary postoperative anticoagulant to heparin in patients receiving ventricular assist devices...
  52. ncbi The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update
    Margaret Prechel
    Assistant Professor, Department of Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA
    Semin Thromb Hemost 34:86-96. 2008
    ..Important drug-specific limitations and dosing and monitoring guidelines must be respected for patient safety. Issues still exist regarding the optimal clinical management of HIT...
  53. ncbi Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation
    Derek R Kieta
    Department of Anesthesiology, The University of Alabama at Birmingham, 619 South 19th Street, Birmingham, AL 35249 6810, USA
    Anesth Analg 96:956-8, table of contents. 2003
    ..This case describes the impact of argatroban and off-pump coronary revascularization on hemostasis as assessed by conventional hemostatic measures and Thrombelastography in a patient with heparin-induced thrombocytopenia...
  54. ncbi [Heparin induced thrombocytopenia and anticoagulation in renal replacemant therapy]
    Thorsten Steinfeldt
    Klinik für Anästhesie und Intensivtherapieam Universitätsklinikum Giessen und Marburg, Standort Marburg
    Anasthesiol Intensivmed Notfallmed Schmerzther 43:304-10; quiz 312. 2008
    ..Furthermore it has to be proven whether the combination of alternative anticoagulants with citrate prolongates circuit halftime of CVVH...
  55. ncbi Preventing complications in heparin-induced thrombocytopenia. Alternative anticoagulants are improving patient outcomes
    Lawrence Rice
    Baylor College of Medicine, 6565 Fannin, MS 902, Houston, TX 77030, USA
    Postgrad Med 112:85-9. 2002
    ..Use of alternative anticoagulants is improving patient outcomes. Lepirudin, argatroban, and danaparoid each have advantages and disadvantages; treatment should be tailored to each patient...
  56. ncbi Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jack Hirsh
    Henderson Research Centre, Hamilton Civic Hospitals, 711 Concession Street, Hamilton, Ontario, Canada
    Chest 133:141S-159S. 2008
    ..Three parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in HIT patients...
  57. ncbi Hirudin in heparin-induced thrombocytopenia
    Norbert Lubenow
    Ernst Moritz Arndt University, Greifswald, Germany
    Semin Thromb Hemost 28:431-8. 2002
    ..The choice between the available drugs for HIT, namely lepirudin, danaparoid, and argatroban, has to be made according to the clinical presentation of the patient...
  58. ncbi Treatment of heparin-induced thrombocytopenia
    William E Dager
    Department of Pharmaceutical Services, The University of California, Davis Medical Center, Sacramento 95817, USA
    Ann Pharmacother 36:489-503. 2002
    ..To describe heparin-induced thrombocytopenia (HIT or HIT-2), an immune-mediated adverse reaction to heparin or low-molecular-weight heparin. Available treatment options and considerations in developing a therapy approach are discussed...
  59. ncbi Heparin-induced thrombocytopenia: a review of current pharmacologic treatment
    Ripple Talati
    Cardiovascular Pharmacology, Hartford Hospital, Hartford, USA
    Conn Med 72:275-9. 2008
  60. ncbi Therapeutic considerations in the management of patients with heparin-induced thrombocytopenia
    Lisa M Tong
    Comprehensive Hemostasis and Antithrombotic Service, University of California, San Francisco CA 94143, USA
    Prog Cardiovasc Nurs 17:142-7. 2002
  61. ncbi Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia
    Walter P Jeske
    Department of Thoracic Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL 60153, USA
    Curr Opin Investig Drugs 3:1171-80. 2002
    ..For these situations, and if immediate anticoagulation is needed, the use of a direct thrombin inhibitor with switch-over to warfarin is a useful option. However, optimal dosing regimens have not been established in all cases...
  62. ncbi Comment: treatment of heparin-induced thrombocytopenia
    Maureen A Smythe
    Ann Pharmacother 36:1483-4; author reply 1484. 2002
  63. ncbi Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method
    T Fenyvesi
    Fourth Medical Department, University Hospital, Mannheim, Germany
    Pathophysiol Haemost Thromb 32:174-9. 2002
    ..PiCT ratio reduces differences between both groups with UFH, and argatroban inhibitor-receptor-binding mode plays a role in interaction patterns...
  64. doi Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin
    Theodore E Warkentin
    Thromb Haemost 99:2-3. 2008
  65. ncbi Heparin-induced thrombocytopenia and thrombosis
    Vipul P Patel
    Department of Orthopaedic Surgery, New York University Hospital for Joint Diseases, New York, New York, USA
    Am J Orthop (Belle Mead NJ) 36:255-60. 2007
    ..Therapy for patients suspected of having HITT should begin with immedi ate discontinuation of heparin in any form followed by pharmacologic inhibition with thrombin (e.g., recombinant hirudin [lepirudin], argatroban, danaparoid sodium)...
  66. ncbi Direct thrombin inhibitors: alternatives to heparin
    Leila Mureebe
    Department of Surgery, Section of Vascular Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Vascular 15:372-5. 2007
    ..With increasing volumes of vascular intervention and an aging population, an increase in the need for anticoagulation can be anticipated. This article reviews current viable options and barriers to the use of heparin...
  67. ncbi Heparin-induced thrombocytopenia: a general review
    Joseph M Swanson
    Joseph M Swanson is Assistant Professor, Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA
    J Infus Nurs 30:232-40. 2007
    ..Therapy should include discontinuation of heparin, initiation of a direct thrombin inhibitor, and eventually therapy with warfarin (only after the platelet count is at least 100 x 10(9)/L)...
  68. ncbi A case series describing the use of argatroban in patients on extracorporeal circulation
    Timothy Cornell
    Critical Care Medicine, C S Mott Children s Hospital, University of Michigan, Ann Arbor, Michigan 48109, USA
    ASAIO J 53:460-3. 2007
    ..2 to 3.5 microg/kg/min. Activated clotting times showed good agreement with aPTT. In conclusion, we illustrate that argatroban is a reasonable alternative to heparin anticoagulation for patients requiring ECLS...
  69. ncbi Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia
    Maureen A Smythe
    Department of Pharmaceutical Services, William Beaumont Hospital, Royal Oak, Michigan 48073 6769, USA
    Am J Hematol 71:50-2. 2002
    ..These data suggest that warfarin anticoagulation be postponed in patients with acute heparin-induced thrombocytopenia until substantial recovery of the platelet count has occurred...
  70. ncbi Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Canada
    Thromb Res 110:73-82. 2003
    ..Thus, the DTI should be given alone during acute HIT, with oral anticoagulants deferred until substantial resolution of the thrombocytopenia has occurred...
  71. ncbi Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia
    E Marc Jolicoeur
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Curr Cardiol Rep 9:396-405. 2007
    ..The algorithm also integrates preventive measures directed at decreasing the bleeding risk associated with the antithrombotic and invasive therapies used for HIT and percutaneous coronary intervention...
  72. ncbi Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects
    R Castelli
    Department of Medicine and Medical Specialities Division of Internal Medicine, IRCCS Fondazione Ospedale Maggiore Policlinico of Milan, Via Pace 9 Milan, Italy
    Cardiovasc Hematol Disord Drug Targets 7:153-62. 2007
    ....
  73. ncbi Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors
    Norman E Lepor
    David Geffen School of Medicine at the University of California at Los Angeles, Cedars Sinai Medical Center, Los Angeles, California, USA
    Rev Cardiovasc Med 8:S9-17. 2007
    ..The antiplatelet, anticoagulant, and pharmacokinetic properties of bivalirudin support its use as the anticoagulant of choice for both lower- and higher-risk patients, including those undergoing PCI...
  74. ncbi Treatment options for heparin-induced thrombocytopenia
    Andreas Greinacher
    Institute for Immunology and Transfusion Medicine, Ernst Moritz Arndt University Greifswald, Diagnostikzentrum Saverbruchstrasse, 17487 Greifswald, Germany
    Am J Health Syst Pharm 60:S12-8. 2003
    ....
  75. ncbi Current agents for the treatment of patients with heparin-induced thrombocytopenia
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Curr Opin Pulm Med 8:405-12. 2002
    ....
  76. ncbi Pseudo infantile Refsum's disease: catalase-deficient peroxisomal particles with partial deficiency of plasmalogen synthesis and oxidation of fatty acids
    P Aubourg
    INSERM U342, Hopital Saint Vincent de Paul, Paris, France
    Pediatr Res 34:270-6. 1993
    ..Oxidation of phytanic and pipecolic acids was severely impaired, whereas oxidation of very-long-chain fatty acids and dihydroxyacetone phosphate ..
  77. ncbi Nocardiopsins: new FKBP12-binding macrolide polyketides from an Australian marine-derived actinomycete, Nocardiopsis sp
    Ritesh Raju
    Institute for Molecular Bioscience, The University of Queensland, Carmody Road, St Lucia, Brisbane 4072, Australia
    Chemistry 16:3194-200. 2010
    ..The scope of this racemization was assessed against a selection of natural and synthetic N-acyl pipecolic acids. While the nocardiopsins are not antibacterial, antifungal or cytotoxic, they do exhibit low-micromolar ..
  78. ncbi Masked oxo sulfinimines (N-sulfinyl imines) in the asymmetric synthesis of proline and pipecolic acid derivatives
    F A Davis
    Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19122, USA
    Org Lett 3:759-62. 2001
    ..These amino acids cyclize and are reduced to cis proline and cis pipecolic acids derivatives in high ee and good yield...
  79. ncbi Conformational properties of secondary amino acids: replacement of pipecolic acid by N-methyl-l-alanine in efrapeptin C
    Anita Dutt Konar
    Fakultat fur Chemie, Universitat Bielefeld, D 33501 Bielefeld
    Chem Biodivers 10:942-51. 2013
    ..The MeAla-containing analogs [MeAla(1,3) ]efrapeptin C and [MeAla(1,3,11) ]efrapeptin C inhibit ATP hydrolysis by the A3 B3 complex of A1 A0 -ATP synthase from Methanosarcina mazei Gö1...
  80. ncbi Systemic infusion and local irrigation with argatroban effective in preventing clot formation during carotid endarterectomy in a patient with heparin-induced thrombocytopenia
    Joseph C Serrone
    Department of Neurosurgery, University of Cincinnati College of Medicine and Comprehensive Stroke Center at University of Cincinnati Neuroscience Institute, Cincinnati, Ohio, USA
    World Neurosurg 80:222.e15-8. 2013
    ..A therapeutic dilemma exists when patients with symptomatic carotid stenosis and concomitant heparin-induced thrombocytopenia (HIT) are advised to urgently undergo carotid endarterectomy (CEA) with heparin therapy...
  81. ncbi An efficient lipase-catalyzed enantioselective hydrolysis of (R,S)-azolides derived from N-protected proline, pipecolic acid, and nipecotic acid
    Chia Hui Wu
    Institute of Biochemical and Biomedical Engineering, Chang Gung University, Kwei Shan, Tao Yuan 33302, Taiwan
    Appl Microbiol Biotechnol 97:1581-7. 2013
    ..Moreover, more than 89.1 % recovery of remained (R)-1 is obtainable in five cycles of enzyme reusage, when pH 7 phosphate buffers were employed as the extract at 4 °C...
  82. ncbi Divergent synthesis of 4-epi-fagomine, 3,4-dihydroxypipecolic acid, and a dihydroxyindolizidine and their β-galactosidase inhibitory and immunomodulatory activities
    K S Ajish Kumar
    Bio Organic Division, Bhabha Atomic Research Centre, Mumbai 400085, India
    J Org Chem 78:7406-13. 2013
    ..The bicyclic compound dihydroxyindolizidine (21) reduced the proinflammatory cytokine (IL-1β and TNF-α) levels in the LPS-activated Raw 264.7 cells without showing any enzyme-inhibition activity. ..
  83. ncbi Argatroban anticoagulation in pediatric patients: a literature analysis
    Marcie J Hursting
    Clinical Science Consulting, Austin, TX, USA
    J Pediatr Hematol Oncol 28:4-10. 2006
    ..Due to the limitations of case reports and/or case series, prospective studies with pharmacokinetic analyses are needed to evaluate the use of argatroban in pediatric patients...
  84. ncbi Immobilization of anticoagulant-loaded liposomes on cell surfaces by DNA hybridization
    Hao Chen
    Department of Reparative Materials, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawara cho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Biomaterials 32:7971-7. 2011
    ....
  85. ncbi Stereoselective preparation of lipidated carboxymethyl-proline/pipecolic acid derivatives via coupling of engineered crotonases with an alkylmalonyl-CoA synthetase
    Refaat B Hamed
    Department of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK
    Org Biomol Chem 11:8191-6. 2013
    ..The results illustrate the biocatalytic utility of crotonases in tandem enzyme-catalysed reactions for stereoselective synthesis...
  86. ncbi Effects of smoking on outcomes after acute atherothrombotic stroke in Japanese men
    Naoko Kumagai
    Center of Medical Information Science, Kochi Medical School, Kochi University, Kohasu, Oko cho, Nankoku City, Kochi 783 8505, Japan Integrated Center for Advanced Medical Technologies, Kochi Medical School, Kochi University, Kohasu, Oko cho, Nankoku City, Kochi 783 8505, Japan Electronic address
    J Neurol Sci 335:164-8. 2013
    ..The effects of smoking on clinical outcomes following acute stroke remain controversial...
  87. ncbi Impact of renal function on argatroban therapy during percutaneous coronary intervention
    Marcie J Hursting
    Clinical Science Consulting, Austin, TX, USA
    J Thromb Thrombolysis 29:1-7. 2010
    ..Renal dysfunction may be associated with slower (by minutes) ACT effect decay after argatroban cessation. Argatroban is well tolerated in PCI patients with renal impairment...
  88. ncbi [Heparin-induced thrombocytopenia]
    Ignacio Cruz-Gonzalez
    Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Rev Esp Cardiol 60:1071-82. 2007
    ..This review contains a discussion of the diagnosis and treatment of this syndrome...
  89. ncbi Functional analysis of genes encoding putative oxidoreductases in Aspergillus oryzae, which are similar to fungal fructosyl-amino acid oxidase
    Nobuyuki Yoshida
    Graduate School of Biological Sciences, Nara Institute of Science and Technology, Ikoma 630 0192, Japan
    J Biosci Bioeng 104:424-7. 2007
    ..rFao10 was active toward only sarcosine, of the substrates tested. The functions of the other proteins were also predicted from a phylogenetic analysis...
  90. ncbi Pharmacokinetics of cycloalliin, an organosulfur compound found in garlic and onion, in rats
    Makoto Ichikawa
    Healthcare Research Institute, Wakunaga Pharmaceutical Company, Ltd, 1624 Shimokotachi, Kodacho, Akitakata, Hiroshima 739 1195, Japan
    J Agric Food Chem 54:9811-9. 2006
    ..These findings are helpful for understanding the biological effects of cycloalliin...
  91. ncbi The effect of argatroban on activated protein C resistance
    Salima Shaikh
    Dept of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Am J Clin Pathol 131:828-33. 2009
    ..Argatroban increases the APC resistance ratio, which can mask a diagnosis of APC resistance and, therefore, factor V Leiden. Clinicians should be advised that APC resistance testing for patients receiving argatroban is not valid...
  92. ncbi Argatroban therapy in patients with coronary artery disease and heparin-induced thrombocytopenia
    Ik Kyung Jang
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cardiology 109:172-6. 2008
    ..01), and led to less bleeding (4 versus 15%, p = 0.046). Therefore, in patients with coronary artery disease who develop heparin-induced thrombocytopenia, argatroban provides safe, effective anticoagulation...
  93. ncbi NMDA receptor activity in learning spatial procedural strategies I. The influence of hippocampal lesions
    Maria G Leggio
    IRCCS S Lucia, Rome, Italy
    Brain Res Bull 70:347-55. 2006
    ..These findings indicate that even in the absence of the hippocampal formation the NMDA receptor antagonist found a site of action to influence the acquisition of spatial procedures to search for the platform...
  94. ncbi The effect of ex vivo anticoagulants on whole blood platelet aggregation
    Madeleine L Kalb
    Department of Special Anesthesiology and Pain Management, Medical University of Vienna, Vienna, Austria
    Platelets 20:7-11. 2009
    ..For point-of-care monitoring with immediate analysis after blood withdrawal all tested direct thrombin inhibitors as well as unfractionated heparin can be used as anticoagulants whereas citrate is not recommended...
  95. ncbi Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation
    Stanley Chia
    Cardiology Division, Massachusetts General Hospital, 55 Fruit Street GRB 800, Boston, MA 02114, USA
    Thromb Haemost 101:535-40. 2009
    ..Paradoxically, Medtronic ACT results were higher after argatroban therapy. Understanding this discrepancy is crucial when using ACT to guide invasive cardiac procedures...
  96. ncbi Proline/pipecolinic acid-promoted copper-catalyzed P-arylation
    Cheng Huang
    Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology Ministry of Education, Department of Chemistry, Tsinghua University, Beijing 100084, PR China
    J Org Chem 71:5020-2. 2006
    ....
  97. ncbi Argatroban in extracorporeal membrane oxygenation
    Martin Beiderlinden
    Klinik für Anästhesiologie und Intensivmedizin Universitätsklinikum Essen, Universitat Duisburg Essen, Germany
    Artif Organs 31:461-5. 2007
    ..However, a dose 10-fold lower than that recommended by the manufacturer is sufficient to achieve appropriate anticoagulation in critically ill patients undergoing ECMO...
  98. ncbi Practical issues in the development of argatroban: a perspective
    Jawed Fareed
    Departments of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL 60153, USA
    Pathophysiol Haemost Thromb 32:56-65. 2002
    ..The pharmacological profile of argatroban is unique as this antithrombin drug not only inhibits thrombogenesis but also modulates cellular functions. Because of its broad spectral actions, argatroban will have more expanded indications...
  99. ncbi Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing
    Robert C Gosselin
    Department of Pathology, University of California, Davis Medical Center, Sacramento, Calif 95817, USA
    Arch Pathol Lab Med 128:1142-5. 2004
    ..The effects of DTIs on activated partial thromboplastin time and prothrombin time measurements have been reported previously, but there are limited data on the impact of these anticoagulants on other coagulation tests...
  100. ncbi Mild hypothermia enhances the neuroprotective effects of a selective thrombin inhibitor following transient focal ischemia in rats
    T Kamiya
    Second Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
    Acta Neurochir Suppl 86:195-8. 2003
    ....
  101. ncbi Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia
    J Jolkkonen
    Department of Neurology, University of Kuopio, Finland
    Eur J Pharmacol 372:31-6. 1999
    ..Its neuroprotective efficacy was better than that produced by CGS-19775, and dexmedetomidine was safer with respect to kidney toxicity when compared to NBQX...

Research Grants8

  1. Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    Guy Young; Fiscal Year: 2009
    ..More modern therapies are available but have not been systematically tested in children. This study will determine whether one such medication, bivalirudin is a safer and more effective alterative. ..
  2. FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    Guy Young; Fiscal Year: 2007
    ..Pharmacokinetic analyses as well as safety and efficacy determinations will be made which will provide valuable information on this new anticoagulant for pediatric patients. [unreadable] [unreadable]..
  3. Effects of Vasoactive Drugs on Perfusion in Septic Shock
    Patrick Murray; Fiscal Year: 2005
    ..focusing on prevention and management of septic acute renal failure, as a surrogate endpoint to optimize systemic perfusion in hyperdynamic states. ..
  4. Estrogen and the Aging Blood Brain Barrier
    OAK CHI; Fiscal Year: 2002
    ..The information obtained from our study will be crucially important for the clinical application of estrogen therapy for stroke as well as understanding the pathophysiology of age related cerebrovascular changes. ..
  5. Properties of GABAc Receptors on Retinal Neurons
    Haohua Qian; Fiscal Year: 2005
    ..The information gained from these studies will enhance our knowledge about the physiological function of the GABA-C receptor in the retina, and broaden our understanding of retinal signal processing mechanisms. ..
  6. Neurodevelopmental Apoptosis
    Nuri Farber; Fiscal Year: 2008
    ..abstract_text> ..
  7. Glucocorticoids and Apoptosis of Cerebellar Neural Progenitor Cells
    Nuri Farber; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  8. Urine Antiproliferative Peptide in Interstitial Cystitis
    Susan Keay; Fiscal Year: 2009
    ..Data from these studies should yield valuable information regarding the structure and mechanism of activity for APF, and may also lead to the identification of potential therapies for this disorder. ..